 Cohorts of 3-6 patients receive escalating doses of capecitabine during both induction chemotherapy and concurrent chemoradiotherapy until the maximum tolerated dose MTD is determined. The MTD is defined as the dose preceding that which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. 